Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice

ConclusionsThe NK1 regimen improved vomiting control at cycle 1 and, when introduced at cycle 2, significantly improved both nausea and vomiting. The biased NK1 selection for higher-risk patients may have dampened the differences between groups at cycle 1. These findings support enhanced control of T-DXd-related nausea and vomiting with NK1RA.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research